A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: A report from the gastrointestinal Oncology group of the Japan clinical oncology group, JCOG 9207 trial

Japanese Journal of Clinical Oncology

Volumn 38, Issue 6, 2008, Pages 432-437

  Hamaguchi, Tetsuya ^a   Shirao, Kuniaki ^a,k   Yamamichi, Noboru ^b   Hyodo, Ichinosuke ^c   Koizumi, Wasaburo ^d   Seki, Shigeki ^e   Imamura, Tetsuri ^f   Honma, Hisanobu ^g   Ohtsu, Atsushi ^h   Boku, Narikazu ^h   Mukai, Toshikazu ⁱ   Yamamoto, Seiichiro ^j   Fukuda, Haruhiko ^j   Yoshida, Shigeaki ^h  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b Fukui Prefecture Mental Health Center   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d KITASATO UNIVERSITY HOSPITAL   (Japan)

^e Saku Central Hospital Advanced Care Center   (Japan)

^f 5 N3E8   (Japan)

^g HOKKAIDO CANCER CENTER   (Japan)

^h NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

ⁱ Kure Kyosai Hospital   (Japan)

^j NATIONAL CANCER CENTER   (Japan)

^k OITA UNIVERSITY   (Japan)

more..

Author keywords

5 fluorouracil; Gastric cancer; Methotrexate; Second line chemotherapy

Indexed keywords

ACETAZOLAMIDE; BICARBONATE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; VITAMIN B COMPLEX;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER REGISTRY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIARRHEA; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HEART MUSCLE ISCHEMIA; HUMAN; HYPOKALEMIA; HYPONATREMIA; JAPAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PROGNOSIS; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; WEIGHT REDUCTION; CANCER STAGING; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; STOMACH TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INJECTIONS, INTRAVENOUS; JAPAN; LEUCOVORIN; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 46349091798     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn043     Document Type: Article

References (21)

1. Statistics of Cancer. Center for Information Services. National Cancer Center, Japan, http://ganjoho.ncc.go.jp/public/statistics/pub/ update.html.
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993:72:37-41.
3. Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994:5:189-90.
4. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracill, epidoxorubicin and methotrexate (FEMTX) plus best supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
5. Fernandes DJ, Bertino JR. 5-Fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyuridylate binding to thymidylate synthase by dihydropteroylpolyglutamates. Proc Natl Acad Sci USA 1980;77:5663-7.
6. Cadman E, Heimer R, Davis L. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drug synergism. Science 1979;205:1135-7.
7. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Superiority of sequential methotrexate, fluorouracil and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial. J Clin Oncol 1989;7:1437-46.
8. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12:960-9
9. Perez JE, Lacava JA, Dominguez ME, Rodriguez R, Barbieri MR, Ortiz EH et al. Biochemical modulation of 5-fluoroumcil by methotrexate in patients with advancel gastric carcinoma. Am J Clin Oncol 1998;21:452-7.
10. Dickinson R, Preagrave P, Levi J, Milliken S. Woods R. Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma. Cancer Chemother Pharmacol 1989;24:67-8.
11. Sasaki T, Ota K, Ibayashi J, Sakata Y, Matsuoka T, Ishikawa M et al. Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer. Jpn J Cancer Chemother 1989; 16:2545-55.
12. Japanese Research Society for Gastric Cancer. Response assessment of chemotherapy for gastric carcinoma. Japanese Classification of Gastric Carcinoma. 1st edn Tokyo, Kanchara, 1995,90-104.
13. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993;23:250-7.
14. Cocconi G, DeLisi V, Di Blasio B. Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treatment Rep 1982; 56:1263-6.
15. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253:2061-7.
16. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-8.
17. Ohta J A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-9.
18. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer-a tale of two drugs: Implications for biochemical modulation. J Clin Oncol 1997;15:368-81.
19. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H et al. Phase II trial of paclitaxel by threc-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001;12:1133-7.
20. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Jpn J Cancer Chemother 1994;21:1033-8.
21. Yamao T, Shimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I et al. Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: A report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol. 2004;34:316-22.